Memgen Announces First Patient Dosed in Phase 1 Combination Cohort of MEM-288 Plus Docetaxel in Advanced Non–Small Cell Lung Cancer
Study designed to assess safety and antitumor activity; data intended to inform a planned randomized Phase 2 studyTAMPA, Fla., Aug.…